Navigation Links
Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
Date:8/20/2007

lete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical products and new therapies; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; failure of third-party manufacturers to produce the product volumes required on a timely basis and fluctuations in currency exchange rates. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... 19, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... (Bina), a privately held company based in ... provides a big data platform for centralized management ... Bina,s proprietary on-market Genomic Management Solution, Bina-GMS 1 ... perform fast and scalable analyses to maximize the ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... Nov. 25 Accuray Incorporated,(Nasdaq: ARAY ), ... today,that Vicenza Hospital, Ospedale Civile San Bortolo in Italy ... CyberKnife(R) Robotic,Radiosurgery System. , ... evolved beyond,brain and spine tumors into extracranial applications, such ...
... a,biopharmaceutical company developing regenerative medicine therapeutics from,a patient,s ... acquired a family of,patents and patent applications from ... The patents ... characterization,of the potency of bone marrow-derived cells in ...
... 25 Insmed Inc. (Nasdaq: INSM ), a ... Geoffrey Allan, President and CEO of Insmed, will be presenting ... December 3, 2008, in New York. , ... better educate the investment community on the development of biosimilars. ...
Cached Biology Technology:Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System 2Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System 3t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application 2Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... new breakthrough by scientists at the University of Sheffield has ... colonise the land over 470 million years ago by forming ... published today (2 November 2010) in Nature Communications , ... group worked together with soil-dwelling fungi to ,green, the Earth ...
... characterized by pauses in breathing that can last for ... more than 50 percent of premature infants and is ... part by an underdeveloped central nervous system that can,t ... sleep, AOP is not yet fully understood by scientists ...
... to journalists: Please credit the journal or the American ... Nov. 2, 2010 For the first time in the ... today detection of Bisphenol A (BPA) in fresh and canned ... amounts in the limited sample, however, were almost 1,000 times ...
Cached Biology News:Study shows how ancient plants and soil fungi turned the Earth green 2UMass Medical School study points to genetic link in apnea of prematurity 2
... Sheep polyclonal to Decorin ( ... Antigen: Synthetic ... to amino acids 6-19 of Human ... molecule bone proteoglycan II). ...
... all Programmable and Digital Orbital Shaker. Our durable, ... to make every day use even easier. This ... up to 4 different programs. Its easy recall ... Furthermore, the VSOS-4P has a pulse operation for ...
... The Antibody Validation Service enables early ... further development by providing quantitative data ... limit of each antibody. Furthermore quantitative ... the off-target activity of your antibodies., ...
... is a new generation of microarrays to ... enables you to rapidly elucidate alternatively spliced ... relevant for drug discovery. The service combines ... design and customized analysis with Agilents robust ...
Biology Products: